Table 2.
Secondary preventive cardiovascular prescription medication after myocardial infarction in patients with type 1 diabetes and matched controls without any type of diabetes
| Type 1 Diabetes | No Diabetes | |||
|---|---|---|---|---|
| n = 1403 | n = 1403 | OR (95% CI) | P value | |
| ACEi or ARB | 72.0% | 66.2% | 1.32 (1.12–1.56) | 0.001 |
| Aldosterone antagonist | 5.7% | 4.6% | 1.24 (0.89–1.74) | 0.204 |
| Beta-blocker | 85.2% | 82.8% | 1.11 (0.90–1.27) | 0.318 |
| Oral anticoagulant | 11.7% | 13.7% | 0.82 (0.65–1.04) | 0.101 |
| P2Y12 inhibitor | 69.4% | 64.9% | 1.25 (1.06–1.48) | 0.008 |
| Statin | 81.8% | 82.7% | 0.94 (0.77–1.15) | 0.540 |
Controls were matched with a separate propensity score including sex, age, all co-morbidities listed in Table 1, revascularization by PCI or CABG, ST-elevation, year of index MI, and treating hospital (university versus non-university)
ACEi angiotensin-converting-enzyme inhibitor, ADP adenosine diphosphate, ARB angiotensin receptor blocker, OR odds ratio, CI confidence interval